Ubrelvy (ubrogepant) is a CGRP receptor antagonist, meaning it blocks the activity of calcitonin gene-related peptide, a protein heavily involved in migraine attacks. It belongs to a class of drugs called “gepants” and is specifically approved for treating migraines once they’ve already started, not for preventing them.
How Ubrelvy Targets CGRP
During a migraine, your body releases large amounts of CGRP. This protein binds to receptors on blood vessels and nerves in the brain, triggering a chain reaction: blood vessels dilate, surrounding nerves become inflamed, and pain signals fire from the trigeminal nerve (the major nerve responsible for head and face sensation) up into the brain.
Ubrelvy works by physically blocking the CGRP receptor so the protein can’t latch on. Without that connection, the blood vessel dilation slows, the inflammatory cascade quiets down, and pain signaling is interrupted. It binds to the receptor with extremely high affinity, meaning it competes effectively against the CGRP your body is producing during an attack.
How Quickly It Works
In the ACHIEVE II clinical trial, about 22% of people who took the 50 mg dose were completely pain-free at the two-hour mark, compared to 14% of those who took a placebo. That may sound modest, but complete pain freedom is a high bar. Many more participants experienced meaningful pain reduction short of total freedom. Ubrelvy comes in 50 mg and 100 mg tablets, and you can take a second dose at least two hours after the first if the migraine persists.
How Ubrelvy Differs From Preventive CGRP Drugs
The CGRP drug class includes both acute treatments (taken during a migraine) and preventive treatments (taken regularly to reduce how often migraines occur). Ubrelvy falls squarely in the acute category. You take it when a migraine starts, not on a daily or monthly schedule.
Preventive CGRP therapies work differently. Monthly or quarterly injections and infusions use antibodies that either bind to the CGRP protein itself or block its receptor on a sustained basis. Some other gepants are approved for both acute and preventive use, but Ubrelvy is indicated only for acute treatment.
Why It Matters for People Who Can’t Take Triptans
Before gepants like Ubrelvy arrived, triptans were the primary prescription option for stopping a migraine in progress. Triptans work by constricting blood vessels in the brain. That vasoconstriction makes them off-limits for people with coronary artery disease, peripheral artery disease, uncontrolled high blood pressure, a history of stroke, or other cardiovascular conditions. All triptans carry these contraindications in their FDA labeling.
Ubrelvy does not constrict blood vessels. Because its mechanism targets the CGRP pathway rather than serotonin receptors, it carries no cardiovascular contraindications. For the substantial number of migraine patients who have heart disease or vascular risk factors, gepants fill a gap that existed for decades.
Side Effects
Ubrelvy is well tolerated overall. The most common side effects in clinical trials were nausea (4% at the 100 mg dose, compared to 2% with placebo) and drowsiness or fatigue (3% at 100 mg, versus 1% with placebo). Dry mouth occurred in about 2% of people taking the higher dose. These rates are low enough that most people don’t notice significant side effects.
Drug Interactions and Contraindications
Ubrelvy is broken down in the liver by a specific enzyme. Certain medications that strongly inhibit that same enzyme can cause Ubrelvy levels to build up in your body, so taking them together is contraindicated. Common examples include the antifungals ketoconazole and itraconazole, and the antibiotic clarithromycin. If you take any of these regularly, Ubrelvy is not an option.
It’s also contraindicated in anyone who has had a serious allergic reaction to ubrogepant, including symptoms like difficulty breathing or swelling of the face or throat.